摘要 |
The present invention relates to pharmaceutical compositions comprising inhibitors of raf kinase of formula (I) wherein: R<1> and R<2> are substituents on the phenyl rings; p, which may take the same or different values for R<1> and R<2>, is 0-3, and when p is 2 or 3 each group may be the same or different; R<3> is C1-4alkyl; q is 0-4; R<4> is aryl or cycloalkyl wherein R<4> is optionally substituted with up to 3 substituents or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier with the proviso that <u>N</u>-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide, <u>N</u>-[5-(3-cyclopentylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, <u>N</u>-[5-(3-phenylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide, <u>N</u>-[5-(4-cyclohexylbutyrylamino)-2-methylphenyl]-4-acetoxybenzamide, <u>N</u>-[5-(2-cyclohexylacetylamino)-2-methylphenyl]-4-acetoxybenzamide, <u>N</u>-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-aminobenzamide, <u>N</u>-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-nitrobenzamide, <u>N</u>-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxymethylbenzamide, <u>N</u>-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-methoxycarbonylbenzamide, <u>N</u>-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-2-hydroxybenzamide, <u>N</u>-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-3-hydroxybenzamide, <u>N</u>-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]benzamide, <u>N</u>-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-acetoxybenzamide and <u>N</u>-[5-(3-cyclohexylpropionylamino)-2-methylphenyl]-4-hydroxybenzamide are excluded. Processes for their preparation and their use as therapeutic agents. A particular use is in cancer therapy. |